QuickMIC® finalist in Applied Microbiology International Product of the Year Award
The diagnostic company Gradientech today announces that the QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST) is a finalist in Applied Microbiology International Product of the Year Award 2023.
The Applied Microbiology International Product of the Year award is awarded to a company who has brought to market a ground-breaking commercial product. Special consideration is given to those products that have addressed in some way one, or several, of the UNs Sustainable Development Goals. The product should represent any of the following qualities: a significant advancement in applied microbiology, a particularly innovative design, a substantial achievement or improvement in performance.
“We are very honoured to have Applied Microbiology International recognise our QuickMIC® system and to be shortlisted for the Applied Microbiology Product of the Year. We developed the QuickMIC system based on ground-breaking technology that makes it the fastest AST system for positive blood cultures. The technology also brings susceptibility testing to a completely new level in terms of precision and accuracy.” says Sara Thorslund, co-founder and CEO of Gradientech.
Applied Microbiology International is the oldest microbiology society in the UK, working to bring the microbiology community together across borders and disciplines, to share expert knowledge and achieve common global goals. Applied Microbiology International publishes the leading industry magazine, The Microbiologist, and in partnership with Wiley and Oxford University Press, six internationally acclaimed journals.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.
